Examining the Impact of the Lown Institute's Shkreli Awards on Healthcare Ethics
Explore the Lown Institute's Shkreli Awards spotlighting ethical concerns in healthcare, advocating for transparency and accountability across the industry.
Explore the Lown Institute's Shkreli Awards spotlighting ethical concerns in healthcare, advocating for transparency and accountability across the industry.
The FDA’s approval of Rasonque for pancreatic cancer alters health insurance dynamics, emphasizing coverage needs for high-cost therapies. Explore the implications.
Explore the shifting coverage of GLP-1 medications within employee health plans as companies like Cigna and PepsiCo reassess their commitments amid rising costs.
Understanding how the rising cost of GLP-1 medications influences employer coverage strategies in the U.S. amidst increasing demand for weight management treatments.
Discover how Medicare covers statin therapy for seniors, impacting insurance professionals and their clients managing chronic conditions. Key insights included.
Explore the CMS Medicare GLP-1 Bridge program revolutionizing drug pricing for Medicare beneficiaries with a fixed $50 monthly cost.
Amazon Pharmacy introduces a $50/month delivery service for GLP-1 weight management meds under Medicare, boosting access and convenience for beneficiaries.
Explore key findings on Medicare Part D cancer drug denials, overturn rates, and the need for improved appeals processes from a recent study.
CMS concludes the Part D Premium Stabilization Demonstration, potentially increasing Medicare premiums. Learn how this affects veterans and their coverage options.
Explore the ongoing challenges of PBS drug misuse in Australia, including implications for healthcare regulation and the critical need for effective management strategies.